Ken Griffin Stoke Therapeutics, Inc. Put Options Transaction History

Citadel Advisors LLC

8 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	BUY	$12.24 - $15.92 $12,240 - $15,920	1,000 Added 12.2%	9,200 $113,000
Q2 2024 Aug 14, 2024	SELL	$11.03 - $17.52 $453,333 - $720,072	-41,100 Reduced 83.37%	8,200 $110,000
Q1 2024 May 15, 2024	BUY	$4.12 - $14.17 $200,644 - $690,079	48,700 Added 8116.67%	49,300 $665,000
Q4 2023 Feb 14, 2024	SELL	$3.37 - $5.4 $12,806 - $20,520	-3,800 Reduced 86.36%	600 $3,000
Q3 2023 Nov 14, 2023	SELL	$3.78 - $11.99 $30,996 - $98,318	-8,200 Reduced 65.08%	4,400 $17,000
Q2 2023 Aug 14, 2023	BUY	$7.93 - $13.82 $86,437 - $150,638	10,900 Added 641.18%	12,600 $133,000
Q1 2023 May 15, 2023	SELL	$7.65 - $10.38 $20,655 - $28,026	-2,700 Reduced 61.36%	1,700 $14,000
Q4 2022 Feb 14, 2023	BUY	$7.07 - $15.69 $31,108 - $69,036	4,400 New	4,400 $40,000

124

57.6M

9.3K

35.2K

Ticker STOK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,419,300
Market Cap $436M
Description
Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output to design ASOs to precisely upregulate protein expression. I...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.